Economic aspects of medical erectile dysfunction therapies.
The introduction of safe and effective oral therapies has changed the significance of erectile dysfunction (ED) forever. Seldom has a new drug changed the landscape of pharmacotherapy in so many ways as sildenafil (Viagra, Pfizer). This article highlights the various oral, intracavernosal and intraurethral therapies currently available for ED and evaluates the socio-economic impact of each method.
Anastasiadis
Aristotelis G
AG
Department of Urology, College of Physicians and Surgeons of Columbia University, 161 Fort Washington Avenue, Dana Atchley Pavilion, 11th Floor, New York, NY 10032, USA.
Ghafar
Mohamed A
MA
Burchardt
Martin
M
Shabsigh
Ridwan
R
D001058:Apomorphine / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D018491:Dopamine Agonists / Q000191:economics / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007267:Injections; D008297:Male; D010413:Penis; D010726:Phosphodiesterase Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014521:Urethra
D018491:Dopamine Agonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D001058:Apomorphine